In the studies VIEW 1 and VIEW 2 (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD 1 and 2), patients received aflibercept in monthly or every-second-month regimens, while a comparison group received monthly ranibizumab treatment. All aflibercept treatment regimens demonstrated noninferiority to ranibizumab monthly treatment. Patients receiving monthly aflibercept, 2 mg, gained 10.9 letters of visual acuity on average, whereas those receiving monthly ranibizumab, 0.5 mg, had a mean 8.1-letter gain (P < .01). Other aflibercept-dosed groups in the 2 studies had results similar to those from the patients receiving ranibizumab, and after 3 monthly doses, aflibercept administered every 2 months showed similar efficacy to ranibizumab administered monthly (see Fig 4-14, Table 4-3).